Lucid Capital analyst Elemer Piros initiated coverage of MediciNova (MNOV) with a Buy rating and $11 price target The firm says the company is in a pivotal trial with an anti-inflammatory and neuroprotective agent for amyotrophic lateral sclerosis. The company’s lead drug ibudilast MN-166 reduces harmful neuroinflammation and supports neuronal resilience through multiple interconnected mechanisms, the analyst tells investors in a research note. Lucid sees blockbuster potential for ibudilast MN-166.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNOV: